{"groups":[{"description":"Bortezomib 1.6 mg/m\\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m\\^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).\n\nBortezomib: 1.6 mg/m\\^2 IV Weekly on Days 1, 8, 15 and 22.\n\nRituximab: 375 mg/m\\^2 IV on Day 8 and 22.\n\nValacyclovir: 500 mg orally daily (or acyclovir 200 mg orally twice daily)","id":"FG000","title":"Bortezomib + Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Unable to collect SCT"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Progressive Disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"comment":"(Additonal cycle 3); Bortezomib 1.6 mg/m2, Rituximab 375 mg/m2 (1 additional cycle)","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"type":"Inadequate Response to First Two Cycles"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"comment":"Rituximab 375 mg/m\\^2, Cyclophosphamide 100 mg/m\\^2, Doborubicine 9 mg/m\\^2/day, dexamethasone 40 mg/day (2 cycles)","type":"Inadequate Response to First 3 Cycles"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"comment":"\\+ 1 cycle of 2CdA 3.0 mg/m2, cyclophosphamide 60 mg/m2, rituximab 375 mg/m2","type":"If Adequate Response to First Two Cycles-participants Proceed to Stem Cell Collection"},{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"46 Participants consented, 9 screen failures.","recruitmentDetails":"Recruitment Period: August 2006- March 2013"}